265648-27-9

Upstream product

• 35675-44-6 4-methylphenylacetyl chloride 
• 1775-95-7 2-amino-5-nitrobenzophenone 

Downstream Products

• 265648-28-0 N-(4-amino-2-benzoylphenyl)-2-(4-methylphenyl)acetic acid amide 
• 265648-29-1 N-[3-benzoyl-4-[2-(4-methylphenyl)acetylamino]phenyl]-N^α-tert-butyloxycarbonyl-S-tritylcysteinamide 
• 302969-62-6 4-[3-benzoyl-4-(2-p-tolyl-acetylamino)-phenylcarbamoyl]-butyric acid 
• 302969-60-4 N-[3-benzoyl-4-(2-p-tolyl-acetylamino)-phenyl]-succinamic acid 
• 683275-32-3 N-[3-benzoyl-4-[(4-methylphenyl)acetylamino]phenyl]-(E)-4-nitrocinnamic acid amide 
• 493037-30-2 N-[3-benzoyl-4-(2-p-tolyl-acetylamino)-phenyl]-3-[5-(4-nitro-phenyl)-furan-2-yl]-acrylamide 
• 875119-78-1 6-amino-4-phenyl-3-(p-tolyl)-2(1H)-quinolinone 
• 875119-77-0 6-nitro-4-phenyl-3-(p-tolyl)-2(1H)-quinolinone 

Relevant academic research and scientific papers

Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides

We have developed a 4-nitrocinnamoyl substituted benzophenone as a novel non-thiol farnesyltransferase inhibitor. Replacement of the p-tolyl moiety of our initial lead structure by different para and ortho substituted phenyl residues as well as by 1-naphthyl resulted in derivatives with considerably enhanced activity displaying IC50 values between 42 and 52 nM. These compounds represent novel, readily accessible non-thiol farnesyltransferase inhibitors being more active than the corresponding thiol-containing analogues. Copyright

Structure-activity relationships of novel anti-malarial agents: Part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides

We have developed the [5-(4-nitrophenyl)-2-furyl]acrylic acid substituted benzophenone 4g as a novel lead for anti-malarial agents. Here, we demonstrated that the acyl residue at the 2-amino group of the benzophenone core structure has to be a phenylacetic acid substructure substituted in its para-position with methyl or other substituents of similar size. The trifluoromethyl substituted derivative displayed an IC50 of 47 nM against the multi-drug resistant Plasmodium falciparum strain Dd2.

Use of 2-phenylene diamine derivatives for the treatment of infections

The invention relates to the use of compounds of formula (I), wherein n=0-3; R1, R2=H, alkyl, aryl, heteroaryl, acyl; R3=H, halogen, alkyl, aryl, heteroaryl, arylalkyl, acyl, CN, NO2, R4—X—; R4/

Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-Acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides

We have described 5-(4-propoxycinnamoylamino)-2-(4-tolylacetylamino)benzophenone 6e as a novel lead for anti-malarial agents. Anti-malarial activity of these 5-(4-propoxycinnamoylamino)benzophenones proved to be quite sensitive against variations of the a

Synthesis, molecular modeling, and structure - Activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors

Because of the involvement of farnesylated proteins in oncogenesis, inhibition of the protein-modifying enzyme farnesyltransferase is considered a major emerging strategy in cancer therapy. Here, we describe the structure - activity relationship of a nove

Non-thiol farnesyltransferase inhibitors: The concept of benzophenone- based bisubstrate analogue farnesyltransferase inhibitors

Replacement of the thiol in a benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitor by a carboxylic acid moiety resulted in a marked drop in inhibitory potency. Transformation of these carboxylic acid derivatives into bisubstrate analogues by addition of a lipophilic alkyl chain, which should be able to occupy considerable portions of the farnesyl binding region in the farnesyltransferase's active site, resulted in a regain of the inhibitory activity. The bisubstrate analogues represent new lead structures for non-thiol farnesyltransferase inhibitors. (C) 2000 Editions scientifiques et medicales Elsevier SAS.